Northeast Financial Consultants’s ARK Genomic Revolution ETF ARKG Stock Holding History

Northeast Financial Consultants’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,959	Closed	-$411K	–	336
2022 Q1	$411K	Buy	8,959 +998	+13%	+$47.6K	0.02%	256
2021 Q4	$488K	Sell	7,961 -5,729	-42%	-$396K	0.03%	225
2021 Q3	$1.02M	Sell	13,690 -4,055	-23%	-$340K	0.07%	158
2021 Q2	$1.64M	Sell	17,745 -1,731	-9%	-$147K	0.11%	112
2021 Q1	$1.73M	Buy	19,476 +2,045	+12%	+$203K	0.13%	95
2020 Q4	$1.63M	Buy	17,431 +11,356	+187%	+$905K	0.13%	94
2020 Q3	$386K	Buy	+6,075	New	+$356K	0.03%	200

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Northeast Financial Consultants's ARKG Position: Q2 2022 in Review

Northeast Financial Consultants sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 8,959 shares — an estimated $411K sold.

Northeast Financial Consultants first reported a position in ARKG in Q3 2020 and held it in 7 quarters. The position peaked at $1.73M in Q1 2021. 333 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

Northeast Financial Consultants reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
Northeast Financial Consultants sold 8,959 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $411K.
Northeast Financial Consultants first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 7 quarters.
Northeast Financial Consultants's ARK Genomic Revolution ETF position peaked at $1.73M in Q1 2021.
333 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on Northeast Financial Consultants's 13F filing for Q2 2022, filed 12 Aug 2022.